Lirafugratinib's 46% ORR Clears Approval Bar But Faces Crowded FGFR Field and Payer Headwinds

FDA Conditionally Accepts LYRFIGTU as Brand Name for Lirafugratinib

Elevar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted conditional acceptance of LYRFIGTU as the brand name for lirafugratinib. This investigational drug is currently under FDA Priority Review for the treatment of advanced/metastatic cholangiocarcinoma (CCA) harboring FGFR2 fusion or other rearrangement, with a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2026. Clinical data from the Phase 1/2 ReFocus trial demonstrated a confirmed objective response rate (ORR) of 46% and a median duration of response of 11.8 months in patients with the proposed indication. Elevar is preparing for a potential launch, pending final FDA approval.

• Key Regulatory Milestone Achieved: The FDA has conditionally accepted LYRFIGTU as the brand name for lirafugratinib, marking a significant step towards potential commercialization. Lirafugratinib is currently undergoing FDA Priority Review for advanced/metastatic cholangiocarcinoma (CCA) with FGFR2 alterations, with a PDUFA target action date set for September 25, 2026, indicating an expedited review process.
• Promising Clinical Efficacy Data: In the Phase 1/2 ReFocus trial (NCT04526106), lirafugratinib demonstrated a confirmed objective response rate (ORR) of 46% and a median duration of response of 11.8 months in patients with advanced/metastatic CCA harboring FGFR2 fusion or other rearrangement. These results highlight the drug's potential to offer a new therapeutic option for this challenging cancer.
• Mechanism of Action and Disease Context: Lirafugratinib is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase frequently altered in certain cancers. Cholangiocarcinoma is a rare bile duct cancer, with approximately 8,000 new diagnoses annually in the U.S., underscoring the significant unmet medical need for effective treatments.

The Unmet Need in FGFR2-Altered Cholangiocarcinoma

Despite meaningful progress with FGFR-targeted therapies, advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements remains a disease defined by acquired resistance, limited post-progression options, and substantial patient attrition across lines of therapy. The initial responses observed with selective FGFR inhibitors are frequently followed by resistance mechanisms that constrain long-term disease control.

• Acquired resistance limits durability of FGFR inhibitor responses. Selective pressure from FGFR inhibitors drives temporal heterogeneity, commonly through gatekeeper mutations that bypass inhibitory effects or cause steric hindrance. Resistance mechanisms identified at progression include FGFR2 secondary mutations, as well as emergent alterations such as gain-of-function mutations in PIK3CA and homozygous deletion of CDKN2A/B, underscoring the molecular complexity of resistance evolution.

• Post-progression outcomes are poor, and a substantial proportion of patients become ineligible for further therapy. Following cessation of first-line FGFR inhibitor therapy, median PFS on subsequent chemotherapy or targeted agents was 2.1 months (95% CI 1.6–5.7) and 3.7 months (95% CI 1.5–not evaluable) on a second FGFR inhibitor. Nearly half of patients become ineligible to receive any further systemic therapy after progression on an FGFR inhibitor, with a median OS of only 2.0 months for those who receive no subsequent treatment.

• Significant variability in treatment outcomes is observed across patients. Even within the FGFR2 fusion-positive population, responses to pemigatinib range from rapid progression after a partial response to sustained disease control exceeding 57 months, reflecting heterogeneity that is not yet fully explained by known molecular features.

• First-line randomized trial data, while encouraging, were generated under constrained conditions. The phase 3 FIGHT-302 trial — the largest first-line randomized trial of a targeted therapy for advanced FGFR2-rearranged cholangiocarcinoma — was closed early due to a change in standard of care, with only 167 patients randomized. Median OS was similar between pemigatinib (24.4 months) and chemotherapy (25.0 months), despite pemigatinib demonstrating a superior median PFS of 8.3 versus 6.8 months (HR 0.58 [95% CI 0.39–0.87]) and objective response rate of 47% versus 15%.

• Most patients eventually develop resistance regardless of the agent used, and tumor progression typically occurs within a year. Across FGFR inhibitor studies, median PFS on initial FGFR inhibitor therapy in real-world settings was 6.6 months (95% CI 5.5–8.3), and even in the pivotal futibatinib FOENIX-CCA2 trial, median PFS was 9.0 months, highlighting that durable remissions remain the exception rather than the rule.

Lyrfigtu's Clinical Efficacy in FGFR2-Altered CCA

Several recent clinical trials have evaluated targeted FGFR inhibition in advanced or metastatic CCA with FGFR2 fusions or rearrangements, spanning both second-line and first-line settings. The data collectively demonstrate meaningful objective response rates and progression-free survival benefits, with hyperphosphatemia and ocular toxicity as recurring safety signals across agents.

Lyrfigtu's Place in the Evolving CCA Treatment Landscape

The treatment landscape for advanced/metastatic CCA harboring FGFR2 fusions or rearrangements has undergone substantial transformation, driven by the clinical validation of FGFR-targeted small molecules. Prior to the emergence of these agents, combination gemcitabine and cisplatin represented the standard of care since 2010, with a median overall survival of 11.7 months, and the five-year survival for CCA remained 5–10%. The approval of pemigatinib — a selective inhibitor of FGFR1-3 — by the US FDA in April 2020 for previously treated advanced or metastatic cholangiocarcinoma with FGFR2 gene fusion or rearrangements marked the first targeted therapy approval in this setting. This was supported by the phase 2 FIGHT-202 trial, which, at final analysis with a median follow-up of 45.4 months, demonstrated an objective response rate (ORR) of 37.0% (95% CI 27.9%–46.9%) in patients with FGFR2 fusions or rearrangements, with a median duration of response (DOR) of 9.1 months, median progression-free survival (PFS) of 7.0 months, and median overall survival (OS) of 17.5 months. Infigratinib, another selective ATP-competitive FGFR inhibitor, also demonstrated activity in this population in a phase 2 study, achieving a BICR-assessed ORR of 23.1% (95% CI 15.6–32.2) after a median follow-up of 10.6 months, further establishing FGFR inhibition as a clinically meaningful strategy in previously treated patients.

The field has since advanced toward evaluating FGFR inhibition in the first-line setting. The phase 3 FIGHT-302 trial — the largest first-line randomized trial of a targeted therapy for advanced FGFR2-rearranged CCA — compared pemigatinib (13.5 mg once daily) against gemcitabine plus cisplatin chemotherapy. Despite early closure due to a change in standard of care, the trial enrolled 167 patients and demonstrated a median PFS of 8.3 months in the pemigatinib group versus 6.8 months in the chemotherapy group (hazard ratio 0.58 [95% CI 0.39–0.87]; nominal P=0.0078), with an ORR of 47% versus 15% and a median DOR of 14.2 versus 6.3 months. Median OS was similar between arms at 24.4 versus 25.0 months. In the crossover group receiving second-line pemigatinib (n=42), median PFS was 8.1 months. Real-world and retrospective data have further characterized outcomes following FGFR inhibitor therapy: in a multicentric retrospective analysis of 88 FGFR-altered CCA patients, median PFS on initial FGFR inhibitor was 6.6 months, and among patients who received a second FGFR inhibitor after progression, median PFS was 3.7 months (95% CI 1.5–not evaluable), with an OS of 8.6 months — comparable to the 8.7 months observed with chemotherapy in the same post-progression setting.

Alongside efficacy data, the evolving landscape has been shaped by a growing understanding of resistance mechanisms and toxicity management. Preclinical evidence indicates that KRAS-activated MAPK signaling causes primary resistance to FGFR inhibitors in FGFR2 fusion-positive ICC, and that a subset of human FGFR2 fusion patients exhibits transcriptome profiles reminiscent of KRAS mutant ICC, underscoring the co-mutational spectrum as a significant modifier of therapeutic response. On the safety front, ocular toxicity — including serous retinal detachment (SRD) and central serous retinopathy-like events — has emerged as a clinically relevant adverse event class across FGFR inhibitors. In the infigratinib phase 2 study, central serous retinopathy-like and retinal pigment epithelial detachment-like events occurred in 18 (17%) patients. Case-level data demonstrate that dose interruption and reduction of pemigatinib can lead to complete recovery of SRD while maintaining tumor response, and that sequential use of two different FGFR inhibitors — necessitated by intolerance to the first — can yield clinical benefit. The most common treatment-emergent adverse events with pemigatinib in FIGHT-202 were hyperphosphatemia (58.5%), alopecia (49.7%), and diarrhea (47.6%). Collectively, these data reflect a landscape that has moved from chemotherapy-only management toward biomarker-guided, FGFR-targeted therapy, with ongoing refinement of patient selection, sequencing strategies, and combination approaches.

LYRFIGTU: A New Frontier in FGFR2-Driven Cholangiocarcinoma

The conditional acceptance of LYRFIGTU (lirafugratinib) as a brand name signals a significant step forward for Elevar Therapeutics and, more importantly, for patients battling advanced cholangiocarcinoma (CCA) harboring FGFR2 fusions. This rare and aggressive cancer has seen a paradigm shift with the advent of targeted therapies, yet the challenge of acquired resistance to existing FGFR inhibitors remains substantial.

LYRFIGTU emerges as a promising contender, distinguished as a first-in-class, FGFR2-selective inhibitor. Its design specifically targets and retains activity against certain resistance-associated FGFR2 kinase domain mutations, such as V565L/F/Y, which often render earlier-generation pan-FGFR inhibitors less effective. Clinical data from the ReFocus trial, demonstrating a 46% objective response rate and a median duration of response of 11.8 months, underscore its potential to offer meaningful clinical benefit.

Strategically, this development reinforces the critical need for sophisticated molecular diagnostics. Comprehensive profiling, including RNA sequencing for initial FGFR2 fusion identification and liquid biopsies for monitoring acquired resistance mutations, will be paramount to guide treatment decisions and optimize sequential therapy. Elevar's entry into this competitive space with a differentiated agent could reshape treatment algorithms, particularly for patients who have progressed on other FGFR inhibitors. However, the path forward is not without its complexities. Even with its selectivity, acquired resistance remains a formidable challenge, with new polyclonal FGFR2 mutations (e.g., M538I, L618F) and RTK-MAPK bypass alterations emerging. Furthermore, managing the characteristic FGFR inhibitor toxicities, such as hyperphosphataemia, will be crucial for patient quality of life and treatment adherence. With a PDUFA date set for September 2026, Elevar has a window to prepare for launch while navigating a dynamic competitive environment, emphasizing the need for robust market differentiation and patient access strategies.